Clinical trials: Kidney (Renal Cell) Cancer
Urothelial Carcinoma, Urothelial Carcinoma Bladder
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT03606174
- Testing
- Sitravatinib, Nivolumab, Pembrolizumab
- Where
- 36 sites in United States
- Volunteers
- 260 people
- Sponsor
- Mirati Therapeutics Inc.
Melanoma, Kidney Cancer
Safety and Efficacy of Tag-7 Gene-modified Vaccine in Locally Advanced or Metastatic Malignant Melanoma or Kidney Cancer
This study was designed to assess the safety and efficacy of inactivated tumor cells genetically modified with the TAG-7 gene as immunotherapy for cancer.
- Trial name
- NCT04180774
- Testing
- Tag-7 gene modified inactivated tumor cells
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Stage IV Melanoma, Stage IV Renal Cell Cancer
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
RATIONALE: The drug flt3L may stimulate a person's immune system and help to kill tumor cells. Vaccines made from melanoma cells may make the body build an immune response to and kill their tumor cells.
- Conditions
- Stage IV Melanoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, Recurrent Melanoma
- Trial name
- NCT00019396
- Testing
- flt3 ligand, gp100 antigen, MART-1 antigen
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
This is a Phase II, open-label, safety, pharmacodynamic and efficacy study of entinostat in combination with nivolumab and ipilimumab in subjects with metastatic renal cell carcinoma (RCC) who have progressed on ipilimumab +…
- Trial name
- NCT03552380
- Testing
- Entinostat, Nivolumab, Ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Roberto Pili
Carcinoma, Renal Cell
Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma
The primary objective of this study is to assess the safety and efficacy of ABT-510 in subjects with advanced renal cell carcinoma.
- Trial name
- NCT00073125
- Testing
- ABT-510/Thrombospondin-1 mimetic
- Where
- 18 sites in United States, Netherlands
- Volunteers
- 103 people
- Sponsor
- Abbott
Renal Cell Carcinoma
A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
Single arm, open label, phase II trial. Participants to undergo biopsy of primary tumour followed by 8 weeks of nivolumab therapy followed by nephrectomy. Nivolumab to be continued post-operatively
- Trial name
- ADAPTeR (NCT02446860)
- Testing
- nivolumab
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Royal Marsden NHS Foundation Trust
MSI-H Colorectal Cancer, Melanoma
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.
- Conditions
- MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma, Mesothelioma
- Trial name
- ACROPOLI (NCT04802876)
- Testing
- Spartalizumab, Tislelizumab
- Where
- Spain
- Volunteers
- 184 people
- Sponsor
- SOLTI Breast Cancer Research Group
Solid Tumor, Adult
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
The main purpose of this study is to evaluate the safety and tolerability of EVT801 in subjects with advanced or metastatic solid tumours.
- Trial name
- NCT05114668
- Testing
- EVT801
- Where
- 2 sites in France
- Volunteers
- 32 people
- Sponsor
- Kazia Therapeutics Limited
Breast Cancer, Prostate Cancer
Survivorship Promotion In Reducing IGF-1 Trial
This is a prospective, single-center randomized trial with three arms, and an allocation ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and coach-directed behavioral weight loss versus…
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer
- Trial name
- SPIRIT (NCT02431676)
- Testing
- Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer, Breast Cancer
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05311618
- Testing
- NGM438, Pembrolizumab (KEYTRUDA ®)
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Multiple Myeloma, Renal Failure
High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment
Multiple myeloma (MM) is a malignant plasma cell disorder, characterized by the presence of more than 10 % of clonal plasma cells in the bone marrow.
- Trial name
- IRMYG (NCT03234335)
- Testing
- Data collection
- Where
- 33 sites in Algeria, Belgium and 2 more
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Lung Cancer
Antigen-specific T Cells Against Lung Cancer
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of cancer antigen-specific T cells targeting lung cancer.
- Trial name
- NCT03356808
- Testing
- Lung cancer-specific T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Non Small Cell Lung Carcinoma, Renal Cell Carcinoma
Retifanlimab and Ruxolitinib In Solid Malignancies
The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma.
- Trial name
- PRISM (NCT07219576)
- Testing
- Ruxolitinib, Retifanlimab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Diego
Kidney Cancer
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: Sunitinib and erlotinib may stop the growth of tumor cell by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00425386
- Testing
- erlotinib hydrochloride, sunitinib malate, biopsy
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- OHSU Knight Cancer Institute
Carcinoma, Renal Cell
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
The purpose of this study is to test the safety of an investigational vaccine called TroVax when given in conjunction with Interleukin-2 (IL-2) treatment.
- Trial name
- NCT00083941
- Testing
- TroVax, Interleukin-2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Oxford BioMedica
Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
The purpose of this study is to understand how patients with mRCC respond to the study medicine (called sunitinib) when they receive it as the first line of treatment after finding out the cause for the disease.
- Trial name
- NCT05745142
- Testing
- Sunitinib
- Where
- Turkey (Türkiye)
- Volunteers
- 376 people
- Sponsor
- Pfizer
Kidney Cancer
Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00849186
- Testing
- sunitinib malate, neoadjuvant therapy, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Roswell Park Cancer Institute
Carcinoma, Renal Cell
Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
A multicenter uncontrolled study of sorafenib in patients with unresectable and/or metastatic renal cell carcinoma (RCC) to assess the pharmacokinetic profile, safety and tolerability, and efficacy.
- Trial name
- NCT00586105
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 8 sites in China, Taiwan
- Volunteers
- 39 people
- Sponsor
- Bayer
Metastatic Renal Cell Carcinoma
Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
The purpose study is to evaluate the efficacy and safety of Sorafenib as first line treatment for patients - unsuitable for another approved first line therapy - with advanced RCC in the Middle East Region.
- Trial name
- MERITS (NCT00848640)
- Testing
- Sorafenib
- Where
- Egypt
- Volunteers
- 75 people
- Sponsor
- Egyptian Foundation For Cancer Research
Melanoma, Carcinoma, Renal Cell
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer
Background: Recombinant human interleukin-15 (rhIL-15) is a substance that is naturally produced in the body that has many properties that increase the activity and strength of the immune system, the body s natural defense…
- Trial name
- NCT01021059
- Testing
- rh IL-15
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.